Based on these results, patients who presented with IDacT were likely to have a high level of serum insulin that could promote disease development, and the residual cancer cells may become refractory to chemotherapeutic drugs due to the delayed administration of the next cycle of treatment. The gene discussed is INS; the disease is cancer.